Decision Diagnostics (DECN) Osake Kurssi
Decision Diagnostics Kurssi
Decision Diagnosticsn liikevaihto on supistunut 8,5 % vuodessa viimeisten 13 vuoden aikana 1,98 M USD:een. Decision Diagnosticsn nettomarginaali −1 499,1 % on laskenut verrattuna −291,0 %:iin muutama vuosi sitten.
Decision Diagnostics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Decision Diagnostics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Decision Diagnostics -osakkeesta
The business model of Decision Diagnostics Corp is focused on the development and commercialization of innovative diagnostic testing products. The company specializes in the creation of advanced systems and technologies for point-of-care testing, primarily in the field of diabetes management. Decision Diagnostics Corp aims to provide accurate, cost-effective, and user-friendly solutions to healthcare professionals and patients worldwide. With a strong emphasis on research and development, the company continuously strives to enhance its product offerings and expand its global market presence. Decision Diagnostics Corp's mission is centered on improving patient outcomes and empowering individuals with convenient and reliable diagnostic tools for effective disease management.
Decision Diagnostics Corp is primarily active in the medical and healthcare industries.
The main competitors of Decision Diagnostics Corp in the market are Company XYZ and Company ABC.
Decision Diagnostics Corp is a renowned company that specializes in the development and production of advanced medical devices. With a rich history and background, Decision Diagnostics Corp has become a trusted name in the healthcare industry. The company focuses on innovative solutions that enhance and simplify medical diagnostics, benefiting both patients and healthcare professionals. Decision Diagnostics Corp has consistently delivered cutting-edge technologies and solutions tailored to meet the evolving needs of the medical field. With a strong commitment to quality and excellence, Decision Diagnostics Corp continues to make significant contributions to the advancement of healthcare through its groundbreaking products.
Decision Diagnostics Corp, a prominent stock, has achieved several significant milestones. The company has successfully developed and launched ground-breaking medical diagnostic technologies, such as its patented Genstrip50 and GenUltimate blood glucose diagnostic test strips. These innovative products have gained widespread recognition for their accuracy, affordability, and convenience, revolutionizing the diabetes market. Decision Diagnostics Corp has also established strategic partnerships with global distributors, expanding its market reach. By prioritizing research and development, maintaining high-quality standards, and fostering strong partnerships, Decision Diagnostics Corp continues to position itself as a leader in the healthcare sector with its notable achievements.
Decision Diagnostics Corp primarily operates in the United States.
Decision Diagnostics Corp represents values of innovation, integrity, and sustainability. With a strong corporate philosophy focused on developing cutting-edge diagnostic devices and health solutions, Decision Diagnostics Corp aims to revolutionize the healthcare industry. The company is dedicated to providing accurate and affordable diagnostic testing options, empowering individuals and healthcare professionals alike. Decision Diagnostics Corp prioritizes transparency and ethical practices, ensuring the highest level of quality in all aspects of their operations. By combining advanced technology with a commitment to bettering global health outcomes, Decision Diagnostics Corp is paving the way for a healthier future.
Nykyisellä valuuttakurssilla Decision Diagnostics-osake noteerataan hintaan 0,00 EUR (0,00 USD).
Decision Diagnostics Corp is an American company specializing in the production of innovative solutions in the healthcare sector. The company's business model includes various divisions, including diabetes diagnosis, marketing of medical products, development of blood sugar monitoring technologies, and handling patent disputes. One of Decision Diagnostics' core products is the GenUltimate! glucose disposable test strip system. These test strips are suitable for measuring blood sugar levels in diabetic patients and can be used by both patients and medical professionals. With the use of special reagents and sensors, the test strips are highly accurate and can deliver results within a few seconds. The company has also developed specialized software that allows for storing and monitoring test results on a smartphone or tablet. Another product offered by Decision Diagnostics includes various medical devices for blood sugar monitoring, such as blood glucose meters and continuous glucose monitoring devices. These devices can help better control the blood sugar levels of diabetic patients and avoid potential complications. In addition to manufacturing medical products, Decision Diagnostics is also active in the field of patents. The company holds a number of patents in the area of diabetes diagnosis and monitoring, allowing it to protect its products and technologies from competition. Furthermore, the company is involved in various patent disputes with other companies offering similar products or technologies. Another business division of Decision Diagnostics is the marketing of medical products and services. The company works closely with various healthcare organizations and partners to sell its products and offer its services. This includes training and education for medical professionals to facilitate the use of Decision Diagnostics' products. Overall, Decision Diagnostics offers a wide range of products and services in the healthcare sector. The company relies on innovative technologies and products to sustainably improve the diagnosis and monitoring of diabetes. Through its patent disputes and close collaboration with different partners, Decision Diagnostics is able to expand its market position and successfully market its products and services.
Liikevaihtoa ei voida laskea Decision Diagnostics:lle tällä hetkellä.
Voittoa ei voida laskea Decision Diagnostics:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Decision Diagnostics:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Decision Diagnostics:lle tällä hetkellä.
Decision Diagnostics:n Eulpool-laatuscore on 2/10.
Decision Diagnostics:n ISIN on US2434431084. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Decision Diagnostics:n WKN on A1JQT2. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Decision Diagnostics:n ticker on DECN. Tämä pörssinoteeraus käytetään Decision Diagnostics-osakkeiden kauppaan pörssissä.
Decision Diagnostics osake
Decision Diagnostics vertaisryhmä
Decision Diagnostics Ticker
Decision Diagnostics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Decision Diagnostics:sta
Meidän osakeanalyysimme Decision Diagnostics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Decision Diagnostics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: